• Proceedings of the PSK Conference
• /
• 2001.04a
• /
• pp.191.2-192
• /
• 2001

• Proceedings of the PSK Conference
• /
• 2001.04a
• /
• pp.191.1-191.1
• /
• 2001

• Proceedings of the PSK Conference
• /
• 2001.04a
• /
• pp.243.1-243.1
• /
• 2001

• Bulletin of the Korean Chemical Society
• /
• v.32 no.4
• /
• pp.1127-1128
• /
• 2011

• Bulletin of the Korean Chemical Society
• /
• v.32 no.10
• /
• pp.3553-3554
• /
• 2011

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2003.10b
• /
• pp.84-85
• /
• 2003

The process of drug development has seen major changes over the last two decades with the movement away from standard small molecule drug discovery programs, through computer-assisted drug design methodologies towards biotechnologically derived products. The aim of duplication of endogenously active materials to be administered exogenously has enormous impact on development practices and evaluation of safety.(omitted)

• The KIPS Transactions:PartD
• /
• v.13D no.7 s.110
• /
• pp.977-984
• /
• 2006

This paper is intended to trace and management of drug based on RFID Technology at a circulation market, from manufacturer to end user, of drug. To avoid counterfeit and generic drug and establish of order in the circulation of drug, at the moment of manufacturing, tags for each bottle and each box are tagged. and then from factory to hospital, through whole logistics, e-pedigree for the drug is made and monitored. Using inventory information, it is easy to manage and control stock of drug. In addition to, RFID System enables storing and delivery to be simple, process time to be shortened. As this research is to study of applying RFID to drug, in this paper, standard RFID code for drug is suggested and tried to apply domestic middle win. Finally, the result of tag pattern design and how to tag for the drug based on 90Mhz is proposed

• Journal of Pharmacopuncture
• /
• v.19 no.1
• /
• pp.7-15
• /
• 2016

Objectives: Malaria has been a major global health problem in recent times with increasing mortality. Current treatment methods include parasiticidal drugs and vaccinations. However, resistance among malarial parasites to the existing drugs has emerged as a significant area of concern in anti-malarial drug design. Researchers are now desperately looking for new targets to develop anti-malarials drug which is more target specific. Malarial parasites harbor a plastid-like organelle known as the 'apicoplast', which is thought to provide an exciting new outlook for the development of drugs to be used against the parasite. This review elaborates on the current state of development of novel compounds targeted againstemerging malaria parasites. Methods: The apicoplast, originates by an endosymbiotic process, contains a range of metabolic pathways and housekeeping processes that differ from the host body and thereby presents ideal strategies for anti-malarial drug therapy. Drugs are designed by targeting the unique mechanism of the apicoplasts genetic machinery. Several anabolic and catabolic processes, like fatty acid, isopenetyl diphosphate and heme synthess in this organelle, have also been targeted by drugs. Results: Apicoplasts offer exciting opportunities for the development of malarial treatment specific drugs have been found to act by disrupting this organelle's function, which wouldimpede the survival of the parasite. Conclusion: Recent advanced drugs, their modes of action, and their advantages in the treatment of malaria by using apicoplasts as a target are discussed in this review which thought to be very useful in desigining anti-malarial drugs. Targetting the genetic machinery of apicoplast shows a great advantange regarding anti-malarial drug design. Critical knowledge of these new drugs would give a healthier understanding for deciphering the mechanism of action of anti-malarial drugs when targeting apicoplasts to overcome drug resistance.

• Biomolecules & Therapeutics
• /
• v.23 no.6
• /
• pp.493-509
• /
• 2015

Antibody-drug conjugates utilize the antibody as a delivery vehicle for highly potent cytotoxic molecules with specificity for tumor-associated antigens for cancer therapy. Critical parameters that govern successful antibody-drug conjugate development for clinical use include the selection of the tumor target antigen, the antibody against the target, the cytotoxic molecule, the linker bridging the cytotoxic molecule and the antibody, and the conjugation chemistry used for the attachment of the cytotoxic molecule to the antibody. Advancements in these core antibody-drug conjugate technology are reflected by recent approval of Adectris$^{(R)}$(anti-CD30-drug conjugate) and Kadcyla$^{(R)}$(anti-HER2 drug conjugate). The potential approval of an anti-CD22 conjugate and promising new clinical data for anti-CD19 and anti-CD33 conjugates are additional advancements. Enrichment of antibody-drug conjugates with newly developed potent cytotoxic molecules and linkers are also in the pipeline for various tumor targets. However, the complexity of antibody-drug conjugate components, conjugation methods, and off-target toxicities still pose challenges for the strategic design of antibody-drug conjugates to achieve their fullest therapeutic potential. This review will discuss the emergence of clinical antibody-drug conjugates, current trends in optimization strategies, and recent study results for antibody-drug conjugates that have incorporated the latest optimization strategies. Future challenges and perspectives toward making antibody-drug conjugates more amendable for broader disease indications are also discussed.

• Food Industry And Nutrition
• /
• v.13 no.2
• /
• pp.34-40
• /
• 2008